Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/clients/e018409a36d8d382bd5c9d12746db954/sites/oncodesign-joomla.propulse.dev/plugins/system/helix3/core/classes/menu.php on line 89


Orient at a very early stage research and development of your therapeutic solutions for resistant and unresponsive patients

OncoSNIPE is the Etiology activity’s first technology. Based on the implementation of bio-informatics, artificial intelligence, statistical learning and semantic enrichment approaches, it is designed to identify and characterize patients resistant to cancer treatments. It aims to provide guidance to therapeutic specialists on how to treat a patient or to a pharmaceutical firm on how to develop new drugs and, ultimately, to reduce therapeutic failure rates.

Oncodesign has made substantial investments in the development of the OncoSNIPE technology. The four-year project is conducted in partnership with Expert System, Sword, and Acobiom, and four academic institutions, including two cancer research centers—Unicancer, Strasbourg university hospital, the Centre Georges François Leclerc (Dijon) and Institut Paoli Calmettes (Marseille). Initially, three indications representing resistance mechanisms in oncology are being covered—breast, pancreatic and lung cancer. OncoSNIPE plans to enroll 600 patients, and their clinical, genomic and medical imaging data is subject to longitudinal monitoring.

The OncoSNIPE project represents an aggregate investment of €12 million and will enrich Oncodesign’s service offering and partnerships:

  • Identification of populations resistant and/or unresponsive to treatments and caracterization of related therapeutic targets, to orient the discovery of new precision therapies in oncology
  • Data analytics in connection with patient treatment, supporting the diagnostic assessment of resistant diseases for healthcare facilities
  • Data analytics in connection with clinical trials targeting sub-populations of patients resistant to anti-cancer therapies.

If you would like further information, contact us today.